Bodansky (1954a) recently described a method for the determination of serum isomnerase and examined the extent to which the serum enzyme activity can be correlated with clinical and biochemical evidence of tumour growth. He found good correlation in breast and prostatic cancer (Bodansky, 1954b (Bodansky, , 1955 .
involving the cellular elements of the blood.
MIIATERIALS AND METHODS
The serum phosphohexose isomerase activity was determined according to the mnethod of Bodansky (1954a) . This determination was carried out on fresh serum obtained from normal controls, patients with variousnon-malignantdiseaseswith normal leukocyte counts, patients with chronic myelocytic and chronic lymphocytic leukaemia, and patients with leukocytosis due to infection. Many of the leukemia group were under treatment at the time of isomerase estimation. Those patients with chronic myelocytic leukemia were receiving radiation or dimethylsulphonoxylbutane (Myleran®), and those with chronic lymphocytic leukemia, radiation or p-(Di-2-chloroethylamino)-phenylbutyric acid (CB1348). leukemia group there would seem to be parallel increases in the serum isomerase and the absolute granulocyte count of the peripheral blood. Fig. 2 Bodansky (1954b Bodansky ( , 1955 has suggested that the rise in serum isomerase in metastatic malignancy may be due to either an excessive production of the enzyme in the new growth or to the easier access into the blood stream of the enzyme from the normal tissues in juxtaposition to the invading tumour. The high levels in chronic myelocytic leukemia may be due to increased production of the enzyme by the leukemic cells or more rapid loss of enzyme from the cells into the serum. Although the total leukocyte count and the granulocyte count were found to be elevated in the infection group, the isomerase was for the most part within normal limits. However, the total granulocyte counts in this group still fell far below those obtained in chronic myelocytic leukemia.
Another possible explanation of the high levels found in chronic myelocytic leukemia might be that bone erosion from the rapidly proliferating myeloid series expanding the medullary cavity facilitates the liberation of isomerase from adjacent tissue. However, the bone marrow invasion and replacement in chronic lymphocytic leukemia is without such an effect on the serum isomerase.
SUMMARY
The serum phosphohexose isomerase acivity was estimated in a normal group and in patients with non-malignant disease, chronic myelocytic and chronic lymphocytic leukemia and leukocytosis due to acute infectious processes. It was found to be elevated in chronic myelocytic leukemia but not in the other groups. In the chronic myelocytic group the isomerase levels fell following treatment.
